Khondrion, the clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease, starts 2019 with the launch of its new website.

As the company continues to advance its proprietary science through a wholly-owned clinical and preclinical pipeline of potential medicines, the launch of its new website signals the start of an important year for the company.

Prof. Dr. Jan Smeitink, Chief Executive Officer of Khondrion, said: “We have made significant progress over the past six years building our preclinical and clinical pipeline of potential medicines that could be transformative for patients and 2019 will be an important year for progress towards that goal.

“Our lead asset, KH176, which has been in development since 2012 to treat a range of mitochondrial diseases, is expected to enter its phase IIb trial this year – a significant milestone for this potential medicine. The trial will allow us to examine further the positive profile we have seen in earlier studies and to confirm the true treatment effect on mitochondrial disease-related symptoms.

“Launching our company’s new website this year also gives us the opportunity to share more up to date information on our research progress and the diseases we want to treat. Our research impacts so many outside Khondrion – be it the external researchers we’re collaborating with, our funding partners, the patients and families involved in our trials and the broader community of patients and families for whom we are pursuing innovative new treatment options. As our research continues we hope www.khondrion.com can become a trusted source of information for all audiences.

“I look forward to updating everyone on our scientific progress throughout 2019.”

 

 About Khondrion

Khondrion is a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease. Founded by Prof. Jan Smeitink, a world-leader in mitochondrial medicine, the company is advancing its proprietary science through a wholly-owned clinical and preclinical small molecule pipeline of potential medicines.  

Khondrion’s lead asset, KH176, is a potential first-in-class oral small molecule in phase IIb clinical development to treat a range of mitochondrial diseases including MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) spectrum disorders. It has been granted Orphan Drug Designation for MELAS spectrum disorders and Leigh disease in Europe and for all inherited mitochondrial respiratory chain disorders in the USA. 

The company’s in-house discovery engine is using unique live-cell imaging technologies, patient-derived cell lines and predictive cell-based disease models to build a portfolio of promising compounds. Active discovery programmes are underway developing new therapies, biomarkers and new read-out technologies in the field of mitochondrial diseases.

To accelerate the discovery and development of its potential medicines for mitochondrial diseases, Khondrion collaborates with a global clinical and academic network and patient organisations internationally. Khondrion is headquartered in Nijmegen, The Netherlands. For more information visit www.khondrion.com